Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Rheumatology Reviews
  4. Volume 21, Issue 1
  5. Article
Volume 21, Issue 1
  • ISSN: 1573-3971
  • E-ISSN: 1875-6360

Abstract

Introduction/Background

Devic’s syndrome is a rare autoimmune disorder that occurs when the body's immune system damages and mistakenly attacks the optic nerves and spinal cord, leading to numerous neurological symptoms such as inflammation, weakness, numbness, and vision problems. Rituximab has mainly been utilized as an immunosuppressive therapy for patients with Devic’s syndrome. Although evidence has shown that rituximab is efficient and well tolerated in treating patients with Devic’s syndrome, there is the possibility of rituximab exacerbating severe psoriasis and psoriatic arthritis flare.

Case Presentation

In this paper, we describe a case of a 58-year-old female with Devic’s syndrome, blindness, and neurological involvement who responded exceptionally well to rituximab but developed a severe flare of psoriatic arthritis. After withdrawing from the use of rituximab, her psoriatic arthritis symptoms had resolved. However, she did have another episode of blindness, and rituximab was started once again. Although her vision improved, her psoriatic arthritis symptoms had reoccurred. The patient was switched to eculizumab and ustekinumab, which controlled both her psoriatic arthritis and Devic’s syndrome.

Conclusion

Very few reports have identified rituximab to induce a flare-up of psoriatic arthritis, raising uncertainty regarding its potential effects on psoriatic symptoms. The precise mechanism underlying the exacerbation of psoriatic arthritis by rituximab remains uncertain. This case report highlights that rituximab can worsen psoriasis and psoriatic arthritis, and that the complexities of Devic’s syndrome may require medication adjustments.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crr/10.2174/0115733971275981240221062257
2024-02-29
2025-05-21

  • From This Site

    /content/journals/crr/10.2174/0115733971275981240221062257
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ShumwayC.L. PatelB.C. De JesusO. Neuromyelitis Optica (NMO, Devics Disease).StatPearls.Treasure Island, FLStatPearls Publishing2023
     [Google Scholar]
  2. HanifN. AnwerF. Rituximab.Treasure Island, FLStatPearls Publishing2023
     [Google Scholar]
  3. KezukaT. UsuiY. YamakawaN. MatsunagaY. MatsudaR. MasudaM. UtsumiH. TanakaK. GotoH. Relationship between NMO-antibody and anti-MOG antibody in optic neuritis.J. Neuroophthalmol.201232210711010.1097/WNO.0b013e31823c9b6c22157536
     [Google Scholar]
  4. SinghalB. JadeJ.D. BansiS. Rituximab in neuromyelitis optica spectrum disorders: Our experience.Ann. Indian Acad. Neurol.201720322923210.4103/aian.AIAN_499_1628904454
     [Google Scholar]
  5. ChanK.H. LeeC.Y. Treatment of neuromyelitis optica spectrum disorders.Int. J. Mol. Sci.20212216863810.3390/ijms2216863834445343
     [Google Scholar]
  6. DassS. VitalE.M. EmeryP. Development of psoriasis after B cell depletion with rituximab.Arthritis Rheum.20075682715271810.1002/art.2281117665440
     [Google Scholar]
  7. AlahmariHS AlhowaishNY OmairMA Rituximab-induced psoriasis in a patient with granulomatosis with polyangitis treated with adalimumab.Case Rep Rheumatol20192019545086310.1155/2019/5450863
     [Google Scholar]
  8. GraalmannT. BorstK. ManchandaH. VaasL. BruhnM. GraalmannL. KosterM. VerboomM. HallenslebenM. GuzmánC.A. SutterG. SchmidtR.E. WitteT. KalinkeU. B cell depletion impairs vaccination-induced CD8+ T cell responses in a type I interferon-dependent manner.Ann. Rheum. Dis.202180121537154410.1136/annrheumdis‑2021‑22043534226189
     [Google Scholar]
  9. ZhongW. XuX. ZhuZ. YangL. DuH. XiaZ. YuanZ. XiongH. DuQ. WeiY. LiQ. Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma.Int. J. Oncol.20185251528153810.3892/ijo.2018.429929512700
     [Google Scholar]
  10. AlasS. EmmanouilidesC. BonavidaB. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis.Clin. Cancer Res.20017370972311297268
     [Google Scholar]
  11. SteenE.H. WangX. BalajiS. ButteM.J. BollykyP.L. KeswaniS.G. The role of the anti-inflammatory cytokine interleukin-10 in tissue fibrosis.Adv. Wound Care20209418419810.1089/wound.2019.103232117582
     [Google Scholar]
  12. WaleckiJ. LebkowskaU.M. CwikłaJ. WaleckaI. WaleckiJ. Psoriatic arthritis.Pol. Przegl. Radiol. Med. Nukl.201378171710.12659/PJR.88376323493653
     [Google Scholar]
  13. Silfvast-KaiserA.S. HomanK.B. MansouriB. A narrative review of psoriasis and multiple sclerosis: Links and risks.Psoriasis20199819010.2147/PTT.S18663731687363
     [Google Scholar]
  14. HeldF. KleinA.K. BertheleA. Drug treatment of neuromyelitis optica spectrum disorders: Out with the old, in with the new?ImmunoTargets Ther.2021108710110.2147/ITT.S28765233777853
     [Google Scholar]
/content/journals/crr/10.2174/0115733971275981240221062257
Loading
Rituximab Induced Flare of Psoriatic Arthritis in a Patient with Devic's Syndrome: A Case Report
Curr. Rheumatol. Rev. 21, 109 (2025); https://doi.org/10.2174/0115733971275981240221062257
/content/journals/crr/10.2174/0115733971275981240221062257
/content/journals/crr/10.2174/0115733971275981240221062257
Loading

Data & Media loading...


  • Article Type:     Case Report
Keyword(s): Rituximab, psoriatic arthritis, devic's syndrome, inflammation, autoimmune disorder, numbness

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test